| pubmed-article:12730520 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12730520 | lifeskim:mentions | umls-concept:C0032533 | lld:lifeskim |
| pubmed-article:12730520 | lifeskim:mentions | umls-concept:C0039483 | lld:lifeskim |
| pubmed-article:12730520 | lifeskim:mentions | umls-concept:C0019878 | lld:lifeskim |
| pubmed-article:12730520 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:12730520 | lifeskim:mentions | umls-concept:C0149783 | lld:lifeskim |
| pubmed-article:12730520 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:12730520 | pubmed:dateCreated | 2003-8-18 | lld:pubmed |
| pubmed-article:12730520 | pubmed:abstractText | It has been suggested that patients with giant cell arteritis (GCA) may share a common pathway with atherosclerosis. Furthermore, patients with GCA and polymyalgia rheumatica (PMR), in addition to advanced age, are treated for prolonged periods of time with corticosteroids, a factor that can also accelerate atherosclerosis. Hyperhomocysteinaemia is considered an independent risk factor for atherosclerosis, and might play a role in ischaemic manifestations that occur with a variable frequency during the course of GCA. The purposes of the present study were: (i). to analyse the plasma levels of homocysteine in patients with GCA and PMR, (ii). to determine the influence of corticosteroid therapy on the homocysteine levels and (iii). to analyse if the levels of homocysteine may predict the development of ischaemic complications in patients with GCA. | lld:pubmed |
| pubmed-article:12730520 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12730520 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12730520 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12730520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12730520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12730520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12730520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12730520 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12730520 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12730520 | pubmed:issn | 1462-0324 | lld:pubmed |
| pubmed-article:12730520 | pubmed:author | pubmed-author:BlancoRR | lld:pubmed |
| pubmed-article:12730520 | pubmed:author | pubmed-author:Rodriguez-Val... | lld:pubmed |
| pubmed-article:12730520 | pubmed:author | pubmed-author:Martinez-Tabo... | lld:pubmed |
| pubmed-article:12730520 | pubmed:author | pubmed-author:BartolomeM... | lld:pubmed |
| pubmed-article:12730520 | pubmed:author | pubmed-author:Lopez-HoyosMM | lld:pubmed |
| pubmed-article:12730520 | pubmed:author | pubmed-author:Fernandez-Gon... | lld:pubmed |
| pubmed-article:12730520 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12730520 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:12730520 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12730520 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12730520 | pubmed:pagination | 1055-61 | lld:pubmed |
| pubmed-article:12730520 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:meshHeading | pubmed-meshheading:12730520... | lld:pubmed |
| pubmed-article:12730520 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12730520 | pubmed:articleTitle | Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy. | lld:pubmed |
| pubmed-article:12730520 | pubmed:affiliation | Division of Rheumatology, Hospital Universitario 'Marqués de Valdecilla', Facultad de Medicina, Universidad de Cantabria, Santander, Spain. vmartinezt@medynet.com | lld:pubmed |
| pubmed-article:12730520 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12730520 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12730520 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12730520 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12730520 | lld:pubmed |
